# INTERVIEW: Oxford BioDynamics Increased Capacity and 5th Contract

- Link: https://www.directorstalkinterviews.com/interview-oxford-biodynamics-increased-capacity-and-5th-contract/412761040
- Published: 2018-11-09T07:23:36+00:00
- Author: Giles Arbor

**Oxford BioDynamics plc** (LON:OBD) CEO Christian Hoyer Millar joins DirectorsTalk
to discuss contract number 5 in the Immuno Oncology space. Christian also discusses
proprietary IP and the increased capacity to take on more work.

Oxford BioDynamics Plc is a biotechnology company focused on the discovery and development
of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.

The Company’s award-winning, proprietary technology platform, EpiSwitch™, aims to
accelerate the drug discovery and development process, improve the success rate 
of therapeutic product development and take advantage of the increasing importance
of personalised medicine.

In particular, EpiSwitch™ can reduce time to market, failure rates and the costs
at every stage of drug discovery. Additionally, the technology provides significant
insights into disease mechanisms for drug discovery and product re‐positioning programmes
and enables the personalisation of therapeutics for patients in the context of challenging
pricing environments where improved clinical outcomes are critical.

Share on: